Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 8;14(3):279.
doi: 10.3390/antibiotics14030279.

Effect of Early Administration of Clarithromycin or Azithromycin on Symptoms of Pertussis in Infants

Alberto Eugenio Tozzi  1 , Ileana Croci  1 , Francesco Gesualdo  1 , Carlo Federico Perno  2 , Giulia Linardos  2 , Alberto Villani  3 , Luisa Russo  4 , Ilaria Campagna  5 , Diana Ferro  1 , Elisabetta Pandolfi  1
Affiliations

Effect of Early Administration of Clarithromycin or Azithromycin on Symptoms of Pertussis in Infants

Alberto Eugenio Tozzi et al. Antibiotics (Basel). .

Abstract

Background: A resurgence of pertussis has been observed in several geographic areas in the post-COVID-19 era. Macrolides are the first-choice antibiotics for the treatment of pertussis. Limited data exist on the impact of the early administration of clarithromycin or azithromycin on infants' pertussis symptoms. Methods: This retrospective cohort study analyzed infants enrolled in an enhanced surveillance program for pertussis at a single Italian clinical reference center between 2015 and 2020. All cases were laboratory-confirmed. This study compared outcomes based on the timing of macrolide antibiotic treatment: early administration (within 7 days of cough onset) versus late administration (8 days or later). Key outcomes included cough duration, symptom frequency, and complication rates. Results: We studied 148 infants with confirmed pertussis. The median duration of coughing was 14 days in infants with early administration and 24 days in those with late administration. The occurrence of symptoms differed for apnea (62.6% for early administration; 84.6% for late administration). In a multivariable Cox model, the duration of the cough was lower in infants receiving antibiotics within 7 days from the beginning of the cough compared with those starting later (HR = 0.36, 95% CI: 0.25-0.53, p < 0.001). Clarithromycin was associated with a shorter duration of coughing (HR = 0.42, 95% CI: 0.19-0.92, p = 0.030) independently from other factors. Regarding the occurrence of symptoms, children receiving antibiotics later were three times more likely to experience apnea compared to those treated early (p = 0.008). Conclusions: Early treatment with clarithromycin or azithromycin for infants with pertussis improves clinical symptoms. Clarithromycin may be more effective than azithromycin in shortening coughing. The early administration of antibiotics may also help prevent the spread of disease during the resurgence of pertussis and should be considered regardless of the laboratory confirmation, while taking into account the potential side effects of an unnecessary therapy.

Keywords: azithromycin; clarithromycin; cough; infants; pertussis.

PubMed Disclaimer

Conflict of interest statement

Dr. Tozzi reported receiving a consultancy fee on vaccines from Pfizer and Sanofi. Dr. Gesualdo received speaker honorarium from MSD Italia and Moderna. No other disclosures were reported.

Figures

Figure 1
Figure 1
Duration of cough by macrolide timing through Kaplan-Maier curves.
See this image and copyright information in PMC

References

    1. Hamson E., Forbes C., Wittkopf P., Pandey A., Mendes D., Kowalik J., Czudek C., Mugwagwa T. Impact of pandemics and disruptions to vaccination on infectious diseases epidemiology past and present. Hum. Vaccines Immunother. 2023;19:2219577. doi: 10.1080/21645515.2023.2219577. - DOI - PMC - PubMed
    1. Baker R.E., Park S.W., Yang W., Vecchi G.A., Metcalf C.J.E., Grenfell B.T. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. USA. 2020;117:30547–30553. doi: 10.1073/pnas.2013182117. - DOI - PMC - PubMed
    1. Cohen R., Ashman M., Taha M.-K., Varon E., Angoulvant F., Levy C., Ryback A., Ouldali N., Guiso N., Grimprel E. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect. Dis. Now. 2021;51:418–423. doi: 10.1016/j.idnow.2021.05.004. - DOI - PMC - PubMed
    1. Treharne A., Murthy B.P., Zell E.R., Jones-Jack N., Loper O., Bakshi A., Nalla A., Kuramoto S., Cheng I., Dykstra A., et al. Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions. Vaccine. 2024;42:125997. doi: 10.1016/j.vaccine.2024.05.045. - DOI - PubMed
    1. Lazarus J.V., White T.M., Wyka K., Ratzan S.C., Rabin K., Larson H.J., Martinon-Torres F., Kuchar E., Karim S.S.A., Giles-Vernick T., et al. Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023. Nat. Med. 2024;30:1559–1563. doi: 10.1038/s41591-024-02939-2. - DOI - PMC - PubMed